Cytotoxic Profiling of Endogenous Metabolites Relevant to CFIDS on p53 Variant Human Colon Carcinoma Cell Lines, 2018, Vukmirovic et al

Andy

Retired committee member
Full title: Cytotoxic Profiling of Endogenous Metabolites Relevant to Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) on p53 Variant Human Colon Carcinoma Cell Lines
Abstract
Chemoprophylatic strategies against development of multifactorial diseases utilize compounds to block the multistep events in chronic inflammation and carcinogenesis. The successful chemopreventative candidate must therefore selectively inhibit growth of transformed cells and be administered frequently to confer maximal protection with minimal side effects. In addition to synthetic and exogenous natural compounds, endogenous metabolites represent another class of compounds that exhibit anticarcinogenic and anti-inflammatory properties contributing to proper cell function. To assess the effectiveness of these compounds warrants an understanding of their cytotoxic mode of action.

In this study, p53 variant human colon carcinoma cell lines were chronically exposed to varying concentrations of the endogenous metabolites—phenyl acetate, ursodeoxycholate, and tauroursodeoxycholate—to determine the role of p53-induced cytotoxicity, with p53 mutant and deficient cell lines representing precancerous lesions. Cytotoxicity was assessed using clonogenic assays, and macroscopic colony counts were used to quantify cell survival. The results demonstrate that the bile acids, ursodeoxycholate and tauroursodeoxycholate, exhibit selective cytotoxicity toward nonfunctional p53 cell lines suggesting a p53-mediated role in inhibition of cell clonogenicity and potential chemopreventative properties. Although each compound displays this described effect, the tauroursodeoxycholate demonstrates high significance suggesting it might have practical uses in vivo.
Open access at http://journals.sagepub.com/doi/10.1177/1559325818790999
 
I have major brain fuzz today but cannot see from my read-through much of a link with ME/CFS/CFIDS - they just state that the metabolites they've tested are 'implicated in CFIDS' without so much as a citation. Weird.
 
I have major brain fuzz today but cannot see from my read-through much of a link with ME/CFS/CFIDS - they just state that the metabolites they've tested are 'implicated in CFIDS' without so much as a citation. Weird.

This looks as though they wanted that sweet, sweet CFIDS money and figured mentioning ME was enough to count. :rolleyes:

[Edit: in the newsletter I was more circumspect, but this really burns my biscuits. Is cancer funding so scarce that a research group has to take money from small ME charities? Shameful.]
 
Last edited:
This looks as though they wanted that sweet, sweet CFIDS money and figured mentioning ME was enough to count. :rolleyes:

[Edit: in the newsletter I was more circumspect, but this really burns my biscuits. Is cancer funding so scarce that a research group has to take money from small ME charities? Shameful.]
The National CFIDS Foundation tends to look for researchers to do studies based on the theories of their scientific director.
 
The National CFIDS Foundation tends to look for researchers to do studies based on the theories of their scientific director.

Good to know! Still -- there is literally nothing here. I'm sure their scientific director wanted them to look into the relationship between cancer and ME, not do a study on cancer but mention ME in one, single sentence of their paper (and the title!)
 
Back
Top Bottom